Nanoforming
In 2019, the pharmaceutical industry invested $182 billion in drug development, but only 48 drugs were approved for use.
Strategy
Agrochemical and Custom Manufacturing Industry: Connected Fates
The fate of the agrochemical innovation, development, product launch and production are strongly linked to the parallel development of the fine chemicals and custom manufacturing industry.
Changing Customer Needs in the Supply Chain
As customers engage in more multi-channel interactions, having a deep understanding of these journeys is an essential component for the customer service function, and for ensuring excellence in the overall customer experience.
Outsourcing Services: from Gene to Patient
Rentschler Biopharma SE, headquartered in Laupheim, Germany, is a leading, family-owned, full-service biopharma CDMO. Owing to agile decision making and efficient processes, Rentschler Biopharma is the preferred outsourcing partner for bioprocess development, cGMP manufacturing, as well as elaboration of product approval strategies for over 150 clients worldwide.
Innovative Chemistry Between Mountains and Lakes
Swiss chemical, pharmaceutical and life sciences companies help drive research around the world, and major players have research activities in the US, Singapore, Japan, as well as EU facilities in the United Kingdom and Germany. But do not underestimate the role of the domestic regional clusters and industrial sites.
Promising Sales Profit Levers
At the end of the third quarter, the chemical industry continues to face an economic slowdown, compounded by international trade conflicts, increased political uncertainty, and fundamental changes to the value chain (e. g. the case of electro-mobility.)
Agile Management in the Chemical Industry
The consulting business has a new bandwagon: agility or agile management. Should the chemical industry jump on it or should we let it pass by?
Driving Innovation and Extending Its Global Reach
Last year, Rentschler Biopharma, a German contract development and manufacturing organization (CDMO) for biopharmaceuticals, announced its "Strategy 2025."
